Restraining the BET proteins has proven to be an accurate method to cure a range of chronic diseases including cancer. The hurdle that stands in the way is finding a peptide that can correctly bind and inhibit one of the four domains (to avoid toxic side effects that could come with incorrectly inhibiting another). The ability to artificially create cyclic peptide 3.1C has meant there is now a way to accurately and specifically bind to BRD3-BD1, a bromodomain from one of the BET’s. The relationship between artificial cyclic peptide 3.1C and BRD3-BD1 is important because they demonstrate the ability for different cyclic peptides to engage a single binding pocket through highly specific interactions. There are still lots of challenges and unknowns that are still to be overcome in the world of drug discovery but learning more about the interactions and what affects the strength and selectivity can help us battle a range of cancers and bacterial infections. https://rb.gy/nsuzdd https://rb.gy/bqwbn8
CC AttributionCreative Commons Attribution
Comments